Research Discipline(s): Basic, Translational, Clinical
Primary Title: Lab Director, Cellular Therapy Laboratory, CancerCare Manitoba; Manitoba Centre for Advanced Cell and Tissue Therapy (GMP Facility)
Additional Titles & Affiliations: Assistant Professor, Department of Immunology & Internal Medicine, University of Manitoba
RESEARCH TOPICS
Cell & Tissue Therapy, Hematopoietic Stem Cell Transplantation, Graft-vs-Host Disease
Health Sciences Centre
820 Sherbrook St, MS773M
Winnipeg, MB R3A 1R9
Canada
Research Summary
- Study of pathogenic and therapeutic roles of immune regulatory cells, eg Myeloid-derived suppressor cells, in autoimmune diseases and hematopoietic stem cell transplantation.
- Develop and/or apply novel cellular therapies, eg, Chimeric Antigen Receptor T cells, for the treatment of cancers and non-malignant diseases (autoimmune diseases, myogenic disease, etc.)
Goals
- To explore the pathogenic and therapeutic roles of immune regulatory cells in autoimmune diseases and hematopoietic stem cell transplantation.
- To develop and/or apply novel cellular therapies for the treatment of cancers and non-malignant diseases (autoimmune diseases, myogenic disease, etc.)
- To Establish a point-of-care manufacturing platform for advanced cell therapies, eg, CAR-T, CAR-NK, MSC.
Research Biography
Qingdong Guan is the Lab Director of Cellular Therapy Laboratory, CancerCare Manitoba, and Manitoba Centre for Advanced Cell and Tissue Therapy (GMP Facility). Qingdong completed his medical doctor training in 2001, MSc training in Immunology in 2004 in China, and PhD training at Dept of Immunology, University of Manitoba in 2012. He then did 4 years of post-doctoral training at Regenerative Medicine Program, University of Manitoba. Qingdong won multiple awards and scholarships during his training, such as CBMTG Young Investigator award, MS Society of Canada Fellowship, CIHR Frederick Banting and Charles Best Canada Graduate Scholarship. He has published over 40 peer-reviewed papers on high impact Journals, such as Lancet Neurology, Allergy, Journal of Leukocyte Biology, Molecular Medicine, Biology of Blood and Marrow Transplantation. Qingdong’s research focuses on development of therapeutic vaccines in autoimmune diseases and tumors, pathogenic and therapeutic roles of immune regulatory cells in asthma, autoimmune diseases and HSCT. Some of his works were highlighted by the journals “Molecular Medicine”, “Clinical & Experimental Allergy” and “ASBMT e-News”. Qingdong has participated in several clinical trials, including First Canadian clinical trial-MESCAMS trial, which studied the efficacy of mesenchymal stem cells in treating multiple sclerosis.
Achievements
- List coming soon
-
Featured Publications
- Uccelli A, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurology. 2021, 20(11):917-929.
- Guan Q, Yang B, Warrington R, Mink S, Kalicinsky C, Becker A, Simons E, Peng Z. Myeloid-derived suppressor cells: Roles and relations with Th2, Th17 and Treg cells in asthma. Allergy, 2019, 74(11):2233-2237. doi: 10.1111/all.13829.
- Guan Q, Yun L, Shprirt T, Bhagwat S, Wall D. Inducible IDO-1 and PD-L1 expression as the potency marker for mesenchymal stem/stromal cells. Cytotherapy, 2018, 20(5):639-649.
- Guan Q, Ezzati P, Spicer V, Krokhin O, Wall D, Wilkins J. Interferon Îł induced compositional changes in human bone marrow derived mesenchymal stem/stromal cells. Clinical Proteomics, 2017, 14:26. Doi: 10.1186/s12014-017-9161-1
- Guan Q, Blankstein A, Anjos K, Synova O, Tulloch M, Giftakis A, Yang B, Peng Z, Cuvelier G, Wall D. Functional myeloid-derived suppressor cell subsets recover rapidly following allogeneic hematopoietic stem/progenitor cell transplantation. Biology of Blood and Marrow Transplantation, 2015, 21 (7): 1205-1214.
- Guan Q, Moreno S, Qing G, Weiss C, Lu L, Bernstein C, Warrington R, Ma Y, Wall D, Peng Z. The role and potential therapeutic application of myeloid derived suppressor cells in TNBS-induced colitis. Journal of Leukocyte Biology, 2013, 94(4):803-811.
- Guan Q, Ma Y, Aboud L, Qing G, Weiss CR, Warrington R, Peng Z. Targeting IL-23 by employing a p40 peptide-based vaccine ameliorates murine allergic skin and airway inflammation. Clinical & Experimental Allergy, 2012, 42(9): 1397-1405
- Guan Q, Ma Y, Hillman CL, Qing G, Ma AG, Weiss CR, Zhou G, Bai A, Warrington RJ, Bernstein CN, Peng Z. Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis. Molecular Medicine, 2011, 17 (7-8):646-56.
